Sunshine Biopharma Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
50
- Stock Symbol
-
SBFM
- Investments
-
2
- Share Price
-
$2.84
- (As of Thursday Closing)
Sunshine Biopharma General Information
Description
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
Contact Information
Website
www.sunshinebiopharma.comCorporate Office
- 333 Las Olas Way
- CU4 Suite 433
- Fort Lauderdale, FL 33301
- United States
Corporate Office
- 333 Las Olas Way
- CU4 Suite 433
- Fort Lauderdale, FL 33301
- United States
Sunshine Biopharma Stock Performance
As of 12-Nov-2026, Sunshine Biopharma’s stock price is $2.84. Its current market cap is $2.34M with 824K shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.84 | $2.75 | $2.53 - $464.00 | $2.34M | 824K | 300K | -$189.00 |
Sunshine Biopharma Financials Summary
As of 30-Jun-2026, Sunshine Biopharma has a trailing 12-month revenue of $35.3M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (1,696) | (2,405) | (5,638) | (11,221) |
| Revenue | 35,347 | 36,306 | 34,874 | 24,093 |
| EBITDA | (5,442) | (5,903) | (5,633) | (4,636) |
| Net Income | (5,833) | (5,975) | (5,134) | (4,506) |
| Total Assets | 33,633 | 30,079 | 30,560 | 27,347 |
| Total Debt | 678 | 812 | 952 | 658 |
Sunshine Biopharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sunshine Biopharma Comparisons
Industry
Financing
Details
Sunshine Biopharma Competitors (11)
One of Sunshine Biopharma’s 11 competitors is Ionis Pharmaceuticals, a Corporate Backed or Acquired company based in Carlsbad, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ionis Pharmaceuticals | Corporate Backed or Acquired | Carlsbad, CA | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA |
Sunshine Biopharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Sunshine Biopharma Patents
Sunshine Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250276036-A1 | Composition for the inhibition of nrf2 and uses thereof in cancer therapy | Pending | 20-Apr-2022 | ||
| WO-2023201432-A1 | Composition for the inhibition of nrf2 and uses thereof in cancer therapy | Inactive | 20-Apr-2022 | ||
| US-12624066-B2 | Inhibitors of coronavirus protease | Active | 22-May-2020 | ||
| US-20230234986-A1 | Inhibitors of coronavirus protease | Active | 22-May-2020 | ||
| WO-2021234483-A1 | Inhibitors of coronavirus protease | Inactive | 22-May-2020 | A61P31/12 |
Sunshine Biopharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sunshine Biopharma Acquisitions (2)
Sunshine Biopharma’s most recent deal was a Merger/Acquisition with Nora Pharma for . The deal was made on 20-Oct-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Nora Pharma | 20-Oct-2022 | Merger/Acquisition | Pharmaceuticals | ||
| Atlas Pharma | 01-Jan-2018 | Merger/Acquisition | Laboratory Services (Healthcare) |
Sunshine Biopharma ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.24 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Sunshine Biopharma Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Nora Pharma | Varennes, Canada | 2017 | |
| Atlas Pharma | Montreal, Canada | 2012 |
Sunshine Biopharma FAQs
-
When was Sunshine Biopharma founded?
Sunshine Biopharma was founded in 2006.
-
Where is Sunshine Biopharma headquartered?
Sunshine Biopharma is headquartered in Fort Lauderdale, FL.
-
What is the size of Sunshine Biopharma?
Sunshine Biopharma has 50 total employees.
-
What industry is Sunshine Biopharma in?
Sunshine Biopharma’s primary industry is Drug Discovery.
-
Is Sunshine Biopharma a private or public company?
Sunshine Biopharma is a Public company.
-
What is Sunshine Biopharma’s stock symbol?
The ticker symbol for Sunshine Biopharma is SBFM.
-
What is the current stock price of Sunshine Biopharma?
As of 12-Nov-2026 the stock price of Sunshine Biopharma is $2.84.
-
What is the current market cap of Sunshine Biopharma?
The current market capitalization of Sunshine Biopharma is $2.34M.
-
What is Sunshine Biopharma’s current revenue?
The trailing twelve month revenue for Sunshine Biopharma is $35.3M.
-
Who are Sunshine Biopharma’s competitors?
Ionis Pharmaceuticals, Amgen, Merck & Co., Gilead, and Sarepta Therapeutics are some of the 11 competitors of Sunshine Biopharma.
-
What is Sunshine Biopharma’s annual earnings per share (EPS)?
Sunshine Biopharma’s EPS for 12 months was -$189.00.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
